Fortrea Inc. (FTRE)
The price, the headline numbers and the latest news, in one place.
Fortrea Inc. (FTRE) Stock Price, Analysis & Data
| Bid | 13.74 |
| Market Cap | 1.79B |
| Revenue (ttm) | 2.68B |
| Net Income (ttm) | -85.2M |
| 1.97 | |
| -0.83 | |
| n/a | |
| 16.52 | |
| P/B (ttm) | 3.41 |
| P/S (ttm) | 0.67 |
| Earnings Date | Nov 5, 2026 |
| Ask | 18.81 |
| Volume | 1,140,969 |
| Avg. Volume (20D) | 1,452,601 |
| Open | 18.77 |
| Previous Close | 18.86 |
| Day's Range | 18.46 - 19.14 |
| 52-Week Range | 8.30 - 21.39 |
| Analyst | Buy |
| Price Target | 22 (16.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FTRE
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical deve...
Financial Performance
In 2025, Fortrea's revenue was 2.72B, an increase of 1% compared to the previous year's 2.7B. Earnings were -986.2M, an increase of 200.21%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for FTRE stock is "Buy". The 12-month stock price forecast is 22, which is upside of 16.96% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $678.2M misses estimates by $0, with -4.52% YoY decline.
- EPS of 0.23 exceeds estimates by 0.05, with 21.05% YoY growth.
Analysts project revenue of ... Upgrade
